<div id="readability-page-1"><div><p>Revvity (RVTY) has given investors two fresh data points to assess: new 2025 revenue guidance pointing to mid single digit growth and a collaboration with Eli Lilly that brings AI models into its Signals platform.</p> <p>See our latest analysis for Revvity.</p> <p>Revvity's shares have rebounded in the short term, with a 30 day share price return of 16.9% and a 7 day gain of 8.29%. However, longer term total shareholder returns remain weak, including a 1 year total shareholder return decline of 4.71%, which suggests recent momentum is only starting to offset a tougher few years.</p> <p>If the combination of AI and diagnostics interests you, it could be worth widening your search to other healthcare stocks that may fit a similar theme.</p> <p>With Revvity guiding to steady 2025 revenue, trading around US$112.50 and sitting at roughly a 13% estimated intrinsic discount and only a small 3% discount to analyst targets, is there still a buying opportunity here or is future growth already priced in?</p> <h2>Most Popular Narrative: 1.9% Undervalued</h2> <p>Revvity's most followed narrative puts fair value at US$114.63, only slightly above the last close of US$112.50. This frames the situation as a fairly tight valuation gap built on specific growth and margin assumptions.</p> <p><em>Ongoing shift in product mix toward higher margin, software enabled and consumables driven offerings (e.g., SaaS Signals, reagents, new IDS i20 platform), along with structural cost actions, are expected to materially expand operating and net margins, with 2026 set to start at a higher 28% operating margin baseline.</em></p> <p>Read the complete narrative.</p> <p>Curious what earnings path gets Revvity from today’s margins to those higher levels, and which P/E the narrative assumes by the mid 2020s? The full story links revenue growth, margin expansion and share count changes into a single valuation roadmap.</p> <p><strong>Result: Fair Value of $114.63 (UNDERVALUED)</strong></p> <p>Have a read of the narrative in full and understand what's behind the forecasts.</p> <p>However, there are still clear risks, including China reimbursement and policy changes, as well as ongoing pressure on academic and government funding that could unsettle this earnings path.</p> <p>Find out about the key risks to this Revvity narrative.</p> <h2>Another Angle On Valuation</h2> <p>Revvity screens as good value on one model, trading about 13.4% below an estimated fair value of US$129.89 using our DCF model. That points to an undervalued setup, but it also assumes future cash flows and discount rates hold up. Do you think those inputs are conservative enough?</p> <p>Look into how the SWS DCF model arrives at its fair value.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/cdf799b7-9c94-432a-95de-7099ef88cf60/chart/dcf?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/cdf799b7-9c94-432a-95de-7099ef88cf60/chart/dcf"/><figcaption>RVTY Discounted Cash Flow as at Jan 2026</figcaption></figure><h2> Build Your Own Revvity Narrative</h2> <p>If you see the assumptions differently, or want to stress test the numbers yourself, you can build a personal valuation story for Revvity in just a few minutes: Do it your way.</p> <p>A great starting point for your Revvity research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.</p> <h2>Looking for more investment ideas?</h2> <p>If Revvity has you thinking about what else might be out there, do not stop here. Broaden your watchlist with focused stock ideas curated from our screeners.</p> <ul> <li>Spot potential bargains by checking out these 865 undervalued stocks based on cash flows that align with your expectations on quality and price.</li> <li>Back fast moving themes by scanning these 24 AI penny stocks that are linked to artificial intelligence trends across different industries.</li> <li>Target income opportunities by reviewing these 12 dividend stocks with yields &gt; 3% that may suit a yield focused approach.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

<p>Revvity (RVTY) has updated its 2025 revenue guidance, indicating mid single-digit growth, and announced a collaboration with Eli Lilly to integrate AI into its Signals platform. The stock has seen a short-term rebound, with a 30-day return of 16.9%. However, long-term returns are down 4.71% over the past year. Revvity's shares are currently trading at $112.50, slightly undervalued compared to a fair value estimate of $114.63. Risks include potential changes in China’s reimbursement policies and funding pressures. Investors are encouraged to explore other healthcare stocks with similar themes.</p>

Simplywall

ALPS Medical Breakthrough

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

Eli Lilly

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

VG Health

Health Care Select Sector SPDR

Revvity

iShares US Pharma

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

A Look At Revvity (RVTY) Valuation After 2025 Guidance Update And Eli Lilly AI Collaboration